Last reviewed · How we verify

NCT05097651

CBD for Sleep in People With HIV

Withdrawn Phase 2 Last updated 10 May 2024
What this trial tests

Phase 2 trial testing Cannabidiol oral solution in Sleep Disturbance. Withdrawn.

Timeline
1 April 2021
Primary endpoint
31 August 2023
31 August 2023

Quick facts

Lead sponsorMariana Cherner, PhD
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Start date1 April 2021
Primary completion31 August 2023
Estimated completion31 August 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mariana Cherner, PhD — full company profile →

Who can join

18 and older, any sex, with Sleep Disturbance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will obtain preliminary information about whether, and at what dose, cannabidiol (CBD) may help with insomnia in people living with human immunodeficiency virus (HIV). The study will be a 5-week randomized, double-blind placebo-controlled phase II trial using daily oral CBD doses between 50mg and 600mg. Sleep problems will be measured using a wrist-worn device and by self-report. Performance on tests of thinking skills will be compared before and after CBD/placebo treatment. Positive study results will provide support for the use of CBD as a potential treatment for insomnia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The therapeutic potential of purified cannabidiol.
    O'Sullivan SE, Jensen SS, Nikolajsen GN, Bruun HZ, et al · · 2023 · cited 33× · PMID 37312194 · DOI 10.1186/s42238-023-00186-9

Verify or expand the search:

Other trials of Cannabidiol oral solution

Trials testing the same drug.

Other recruiting trials for Sleep Disturbance

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05097651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing